Progesterone Receptor Negative Not Yet Recruiting Phase 2 Trials for Gemcitabine (DB00441)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03606967Nab-Paclitaxel and Durvalumab With or Without Neoantigen Vaccine in Treating Patients With Metastatic Triple Negative Breast CancerTreatment